Abstract
Background and Aims: Diabetes mellitus is a chronic metabolic disorder affecting global
public health. Since ancient, natural-based compounds are widely used for multiple indications of diabetes.
Methods: The natural-based (-)-Epicatechin has enormous biological functions including antioxidant and
anti-inflammatory activities. This review mainly focuses on the importance of epicatechin in the control
of pathogenesis involved in diabetic mellitus. Additionally, its possible mechanisms involved in beta cell
regeneration, insulin secretion, and insulin sensitivity.
Results: The present article explored the potential antioxidant, mitochondrial protection, and antiinflammatory
properties using the preclinical and clinical model, and also established the role of (-)-
Epicatechin in the mitigation of diabetic-associated complications.
Lastly, the article mentioned the limitation of the use of epicatechin.
Conclusion: This will provide new insight to budding scientists for the development of novel bioactivebased
pharmaceuticals for the management of diabetic mellitus.
Graphical Abstract
[5]
Chun, J. H.; Henckel, M. M.; Knaub, L. A.; Hull, S. E.; Pott, G. B.; Ramirez, D. G.; Keller, A. C. (−)-Epicatechin reverses glucose intolerance in rats housed at thermoneutrality. Planta Med., 2022, 88(09/10), 735-744.
[21]
El-Remessy, A.B.; Ali, T.K.; Pillai, B.A.; Matragoon, S. Epicatechin prevents gliosis and neuronal death in diabetes: Critical role of MMP-7. Invest. Ophthalmol. Vis. Sci., 2009, 50(13), 5375-5375.
[25]
Ahmad, F.; Khalid, P.; Khan, M.M.; Rastogi, A.K.; Kidwai, J.R. Insulin like activity in (−) Epicatechin. Acta diabetologia latina, 1989, 4, 291-300.
[26]
Biswas, M.; Bhattacharya, S.; Karan, T.K.; Kar, B.; Kumar, R.B.; Ghosh, A.K.; Haldar, P.K. Antidiabetic activity and antioxidant activity of Dregeavolubilis fruit in streptozotocin-induced diabetic rats. Asian J. Chem., 2011, 23(10), 4503-4507.
[45]
Villarreal, F.; Moreno‐Ulloa, A.; Ciaraldi, T.; Best, B.; Ramirez‐Sanchez, I.; Ceballos, G.; Henry, R. Clinical pharmacokinetics and preclinical pharmacodynamics of (+)‐epicatechin on cardiometabolic endpoints. FASEB J., 2017, 31, 676-1.